KangStem Biotech Co., Ltd. (KSB)

Kangstem Biotech Co., LTD. (KSB) is developing stem cell therapeutic products which target autoimmune diseases. KSB has developed methods to isolate and to mass culture high purity human umbilical cord blood-derived stem cells (hUCB-SCs). Based on these platform technologies, KSB was able to establish immune-modulating mechanism of hUCB-SCs, and currently conducting clinical trials for the development of stem cell therapeutic products targeting atopic dermatitis (Furestem-AD®), rheumatoid arthritis (Furestem-RA®), and Crohn’s disease (Furestem-CD®). Therapeutic product targeting osteoarthritis (FurestemOA®) is currently on the pre-clinical trial stage. KSB is also conducting research on directly converted neural stem cell (dcNSC) to provide patient specific regenerative medicine for neurological disorder. *

	Start	2018-10-01 existent
	Industry	stem cell therapy
	Industry 2	Furestem-AD® stem cell therapy
	Person	Lee, Tae Wha (KangStem Biotech 201810 CEO)

	Region	Seoul
	Country	Korea, Republic of
	City	n. a. Seoul
		Address record changed: 2018-10-04

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2024-08-24

Picture EBD Group ChinaBio Partnering Forum 2025 Shanghai 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]